PharmaPoint Atopic Dermatitis – Global Drug Forecast and Market Analysis to 2024

“The Report PharmaPoint: Atopic Dermatitis – Global Drug Forecast and Market Analysis to 2024 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. –”

Although the past decade has seen the atopic dermatitis market remain relatively unchanged and a saturated, highly genericized arena, the coming decade could see the launch of the first biologic, which will set a precedent and pave the way for others to follow suit.

By the mid-to-late term of GlobalData’s 2014 to 2024 forecast, Sanofi/Regeneron’s dupilumab is expected to reshape the adult moderate and severe treatment landscape and to slowly enter the market for younger patients with milder forms of the disease.

Other events that are expected to invoke change to the previously stagnant atopic dermatitis market include the launch of a non-steroidal topical from Anacor, AN2728, generic erosion of branded topicals Protopic and Elidel in the US.

Exciting times lay ahead for the atopic dermatitis marketplace, as the above events are due to occur against the backdrop of increasing research into the multiple etiologies that give rise to the disease. With existing unmet need for a better treatment armamentarium for severe, recalcitrant patients and an estimated drug-treated population that hovers around the 110 million mark over the next decade, atopic dermatitis represents an attractive dermatology sector for drug developers, and this should fuel commercial interest into this marketplace.

View Report At :


Key Questions Answered

  • How will the atopic dermatitis market (sales and patient numbers) evolve over the 10-year forecast period from 2014 to 2024?

  • Which brands and specific drug classes did physicians select for their atopic dermatitis patients in 2014 and how do they foresee their prescribing behavior evolving over the next five years?

  • How will the launch of late-stage pipeline therapies such as dupilumab and AN2728 shape the future treatment landscape?

  • What are the remaining unmet needs and opportunities for drug developers within the atopic dermatitis market?

Key Benefits

  • The main drivers of growth in the atopic dermatitis over the 2014-2024 forecast period include the launch of the first biologic; Sanofi/Regeneron’s dupilumab, and continued uptake of calcineurin inhibitors of systemic therapies.

  • Owing to high genericization, no distinct trends in corporate strategy exist within the atopic dermatitis market. However, over the coming decade, the introduction of biologics, in particular interleukin (IL) inhibitors, will emerge as a key future strategy for this marketplace.

  • High unmet need exists for a better treatment armamentarium for severe, recalcitrant patients. This patient segment remains underserved as physicians have few to no pharmacological options following treatment failure with or intolerability to cyclosporine, and as a result physicians often resort to prescribing off-label therapies.

  • Although dupilumab is forecast to gain a foothold in the severe population by late-forecast, it will not completely eradicate the high unmet need within the refractory group in the severe patient segment. There will still be a gap for other novel systemics, as dermatologists stress a desire for more than one treatment option to be added to their armamentarium.

Download Sample copy of this Report at:


  • Overview of atopic dermatitis, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current treatment options.

  • Annualized atopic dermatitis therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2014 to 2024.

  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, and implications for the atopic dermatitis therapeutics markets.

  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of mid-to-late stage pipeline drugs.

  • Analysis of the current and future market competition in the global atopic dermatitis therapeutics markets. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to –

  • Develop and design in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.

  • Develop business strategies by understanding the trends shaping and driving the global atopic dermatitis therapeutics markets.

  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global atopic dermatitis therapeutics markets in the future.

  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

  • Track drug sales in the global atopic dermatitis therapeutics markets from 2014-2024.

  • Organize sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table Of Content

1 Table of Contents 10

1.1 List of Tables 14

1.2 List of Figures 18

2 Introduction 19

2.1 Catalyst 19

2.2 Related Reports 19

2.3 Upcoming Related Reports 20

3 Disease Overview 21

3.1 Etiology and Pathophysiology 21

3.1.1 Etiology 21

3.1.2 Pathophysiology 22

3.2 Symptoms 26

4 Epidemiology 28

4.1 Disease Background 28

4.2 Risk Factors and Comorbidities 28

4.3 Global Trends 29

4.3.1 US 30

4.3.2 France 30

4.3.3 Germany 31

4.3.4 Italy 31

4.3.5 Spain 31

4.3.6 UK 32

4.3.7 Japan 32

4.3.8 China 32

4.3.9 India 33

4.4 Forecast Methodology 33

4.4.1 Sources Used 36

4.4.2 Sources Not Used 41

4.4.3 Forecast Assumptions and Methods 41

4.5 Epidemiological Forecast for Atopic Dermatitis (2014-2024) 42

4.5.1 One-Year Total Prevalent Cases of Atopic Dermatitis 42

4.5.2 Age-Specific One-Year Total Prevalent Cases of Atopic Dermatitis 44

4.5.3 ***-Specific One-Year Total Prevalent Cases of Atopic Dermatitis 45

4.5.4 Age-Standardized One-Year Total Prevalence of Atopic Dermatitis 47

4.5.5 One-Year Total Prevalent Cases of Atopic Dermatitis by Severity 48

4.6 Discussion 50

4.6.1 Epidemiological Forecast Insight 50

4.6.2 Limitations of the Analysis 50

4.6.3 Strengths of the Analysis 51

5 Disease Management 52

5.1 Diagnosis and Treatment Overview 52

5.1.1 Diagnosis 52

5.1.2 Treatment Guidelines 54

5.1.3 Leading Prescribed Drugs for the Treatment of RA 56

5.1.4 Clinical Practice 58

5.2 US 59

5.3 5EU 64

5.4 Japan 71

6 Competitive Assessment 74

6.1 Overview 74

6.2 Strategic Competitor Assessment 75

6.3 Product Profiles – Major Brands 76

6.3.1 Protopic (tacrolimus) 76

6.3.2 Elidel 84

Follow us on LinkedIn:

About us is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.


Mr. Nachiket

State Tower

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-621-2074